Evidence mapPaperPMID 40197830Full record

ReviewDiabetes2025

What Is Gestational Diabetes-Really?

Thomas A Buchanan, Anny H Xiang, Kathleen A Page, Richard M Watanabe

Abstract readReview
In one paragraph

Review in Diabetes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Association ofBiomolecules & biomedicine · 2025
    Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Preconception Perceptions, Knowledge and Behaviours of Women With Gestational Diabetes Mellitus: A Qualitative Study.Health expectations : an international journal of public participation in health care and health policy · 2026
    Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Editorial: Neglected nuances in gestational diabetes.Frontiers in clinical diabetes and healthcare · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Thomas A BuchananDivision of Endocrinology and Diabetes, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA.ORCID 0000-0001-7892-5132
Anny H XiangDiabetes and Obesity Research Institute, University of Southern California, Los Angeles, CA.ORCID 0000-0003-2786-1268
Kathleen A PageDivision of Endocrinology and Diabetes, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA.ORCID 0000-0002-9083-6615
Richard M WatanabeDiabetes and Obesity Research Institute, University of Southern California, Los Angeles, CA.ORCID 0000-0003-1015-0531

Funding

ZOPOLRESTAT IN NORMOTENSIVE, TYPE 1 DIA WITH INCIPIENT NEPHROPATHYM01RR000043 · UNIVERSITY OF SOUTHERN CALIFORNIA · 1985 to 2005
$43.4M
Southern California Clinical and Translational Science InstituteUL1TR001855 · UNIVERSITY OF SOUTHERN CALIFORNIA · 2025 to 2025
$9.1M
Genetics of Beta Cell Failure in Mexican AmericansR01DK061628 · UNIVERSITY OF SOUTHERN CALIFORNIA · 2003 to 2005
$4.4M
PATHOGENESIS OF TYPE 2 DIABETES IN LATINO WOMENR01DK046374 · UNIVERSITY OF SOUTHERN CALIFORNIA · 1993 to 2005
$2.2M
Neuroendocrine Systems involved in Early-life Programming for Obesity and DiabetesR01DK116858 · NIDDK · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Kathleen Alanna Page, ANNY H XIANG · 2022 to 2023
$1.4M
Effects of prenatal exposures to maternal obesity and gestational diabetes on metabolic decline from childhood to adolescence and underlying neurobiological pathwaysR01DK134079 · UNIVERSITY OF SOUTHERN CALIFORNIA · 2025 to 2025
$778k
American Diabetes Association 1-14-ACE-36 7-04-DCS-03 7-09-CTMerck &CoNCATS NIH HHS UL1 TR001855NCRR NIH HHS M01 RR000043NIDDK NIH HHS R01 DK046374NIDDK NIH HHS R01 DK061628NIDDK NIH HHS R01 DK116858NIDDK NIH HHS R01 DK134079Parke-Davis Pharmaceutical ResearchTakeda Pharmaceuticals North AmericaU.S. Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences UL1TR001855U.S. Department of Health and Human Services National Institutes of Health National Center for Research Resources M01RR00043U.S. Department of Health and Human Services National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases R01DK116858 R01DK134079 R01DK46334 R01DK46374 R01D
6 · The paper itself

Abstract

Gestational diabetes mellitus (GDM) is one of the most common medical complications of pregnancy. It is generally defined as glucose intolerance with onset or first recognition during pregnancy. The pathogenesis of GDM has long been attributed to inadequate pancreatic β-cell compensation for the physiological insulin resistance of pregnancy. This defect is thought to resolve after pregnancy but become manifest in later life as an increased risk of diabetes. Examination of mechanisms underlying GDM does not support this commonly held picture. In this Perspective, we present evidence that, like diabetes outside of pregnancy, GDM has no single etiology. It results from multiple causes of a common physiological manifestation, inadequate β-cell function, which leads to a common clinical manifestation, elevated glucose levels. We provide evidence that GDM often represents detection of chronic and progressive β-cell dysfunction that is temporally but not mechanistically related to pregnancy. We provide detailed characterization of the β-cell defect in one high-risk group, Hispanic Americans. Finally, we address some of the clinical and research implications of these findings. ARTICLE HIGHLIGHTS: Gestational diabetes mellitus (GDM) is not one disease but many that share inadequate β-cell function as a common cause for elevated glucose levels. Inadequate β-cell function may result from factors that occur outside of pregnancy, such as autoimmunity, monogenic disorders, obesity, and insulin resistance. Pregnancy-specific causes may exist as well but remain to be defined. Detailed physiological studies in women with obesity reveal that inadequate β-cell function is likely a chronic condition that is detected by routine glucose screening in pregnancy and that worsens over time, leading to diabetes in later life. The authors' studies in Hispanic patients identify obesity and insulin resistance as important causes of β-cell dysfunction, providing a rationale for treating both to prevent diabetes after GDM. Additional work is needed to define the full breadth of underlying causes of GDM as the basis for precision management during and, especially, after pregnancy.

Indexed as

Diabetes, GestationalInsulin-Secreting CellsBlood GlucoseFemaleHumansInsulin ResistancePregnancyBlood Glucose

Identifiers

PMID40197830
PMCPMC12185965

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.